Physician profile
Conan Carter
NPI 1497713804
$2,653.01
in general payments reported to CMS, 2019-2025
22 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $706 · 2023: $617 · 2024: $256 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.40 | 2021-2025 | |
| Novo Nordisk INC | $282.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $278.11 | 2022-2025 | Caplyta |
| Pfizer INC. | $271.03 | 2021-2023 | |
| Lilly USA, LLC | $213.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $207.87 | 2021-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $141.29 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $126.14 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $100.32 | 2022-2024 | Rexulti |
| Medtronic, INC. | $85.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $70.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.98 | 2023-2025 | |
| Exact Sciences Corporation | $55.71 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $41.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.05 | 2023-2024 | Xifaxan, Trulance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $23.38 | 2022 | |
| Esperion Therapeutics, INC. | $22.69 | 2021 | |
| Redhill Biopharma INC. | $20.06 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.86 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.20 | 2023 | Horizant |
| Neurelis, INC. | $12.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conan Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.